Factors influencing p53 expression in ovarian cancer as a biomarker of clinical outcome in multicentre studies. - Wikidata - awgldk - TriplyDB

Factors influencing p53 expression in ovarian cancer as a biomarker of clinical outcome in multicentre studies.

Factors influencing p53 expression in ovarian cancer as a biomarker of clinical outcome in multicentre studies.

http://www.wikidata.org/entity/Q36612301

about

Associations between p53 overexpression and multiple measures of clinical outcome in high-risk, early stage or suboptimally-resected, advanced stage epithelial ovarian cancers A Gynecologic Oncology Group study.p53 autoantibodies as potential detection and prognostic biomarkers in serous ovarian cancer.Potential target antigens for a universal vaccine in epithelial ovarian cancer.Nuclear COMMD1 Is Associated with Cisplatin Sensitivity in Ovarian Cancer The ErbB signalling pathway: protein expression and prognostic value in epithelial ovarian cancer.Modest effect of p53, EGFR and HER-2/neu on prognosis in epithelial ovarian cancer: a meta-analysis p16 and p53 in HPV-positive versus HPV-negative oral squamous cell carcinoma: do pathways differ?The classification of p53 immunohistochemical staining results and patient outcome in ovarian cancer.Potentiation of a p53-SLP vaccine by cyclophosphamide in ovarian cancer: a single-arm phase II study.Loss of SerpinA5 protein expression is associated with advanced-stage serous ovarian tumors.

P2860

Q30437752-3EBEFCF9-6659-4581-AD71-B959ED53552A Q33725961-A3E8C2FD-C3DA-46D1-AE1B-89A88AA74878 Q34159451-17470DFE-BDA4-47F3-8B3F-1D799F9DE53C Q36176287-6B52EC9E-6E92-4ABF-998B-CEF08C25B94C Q36785983-8E8E7A75-53FA-4F63-B26F-3703732810D1 Q37269642-AC347581-D0D1-42A5-B863-13A68EA212AA Q40340859-A6A618B0-0556-463F-95E2-C7017DED9A2F Q43198996-A252D16F-B6E1-42D9-8DE5-6081B695D419 Q46920170-6B237F9D-0624-4C6B-A3B4-81B71BAF1674 Q51531612-EDDDAC66-D1CF-4D9E-9E12-4CE9020E55A0

P2860

Factors influencing p53 expression in ovarian cancer as a biomarker of clinical outcome in multicentre studies.

http://www.wikidata.org/entity/Q36612301

description

2006 nî lūn-bûn

@nan

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

2006年论文

@zh

2006年论文

@zh-cn

name

Factors influencing p53 expres ...... utcome in multicentre studies.

@ast

Factors influencing p53 expres ...... utcome in multicentre studies.

@en

type

label

Factors influencing p53 expres ...... utcome in multicentre studies.

@ast

Factors influencing p53 expres ...... utcome in multicentre studies.

@en

prefLabel

Factors influencing p53 expres ...... utcome in multicentre studies.

@ast

Factors influencing p53 expres ...... utcome in multicentre studies.

@en

P1433

Q36612301-128FEA30-7AFE-4A49-9753-2BF1027C8F5A

P1476

Q36612301-CE298C47-5FD0-4891-B89E-B3FF4DEFB670

P2093

Q36612301-176846E8-B192-45A0-BFFE-9EF82D62624C

Q36612301-261FFF12-4D9A-41CD-9761-42C5B88CA0C2

Q36612301-57ED7750-1B52-4569-8781-AEC5080A479C

Q36612301-70FD9D38-D677-4C1D-8B6B-972A5CDACAAE

Q36612301-740413DF-9EAD-4ADD-9786-D01739912492

Q36612301-8C1185E8-6E3E-4284-835B-B9D170AC5CF7

Q36612301-B3713799-3F9E-444F-9575-52667BDA792A

Q36612301-B7C4A6F7-7FA1-45F4-B0A8-CC895EC5ABE6

Q36612301-CCBB3444-3914-4EC0-BDBA-934D76B7DA9F

Q36612301-D5260FBB-FB13-49E8-8849-3211F6AA2351

P2860

Q36612301-0E74C705-2847-4342-9C92-B5F59D79FF15

Q36612301-1141F2E4-9CC7-44A4-9397-18B7924918DF

Q36612301-16DEE3A7-942A-4191-80EC-7A0D49913921

Q36612301-1C73B4F7-734D-41E1-8B3E-0C755640FBFE

Q36612301-201CAB96-C0D7-4DC9-9DDE-CB4BF034B1B9

Q36612301-2D2895B0-A050-4FF3-AAE8-C6948370557D

Q36612301-356435E9-CF74-486B-9EED-AE9547E80932

Q36612301-360FAFAD-EBBC-4FAA-A77D-6DFCDCDF4000

Q36612301-3EF72765-5A42-4114-B87A-698650D15D3D

Q36612301-41FB53CA-6C89-41F2-A6B7-9CA63B2961DE

P2888

Q36612301-EC1B9DC1-6547-440C-9CF2-D15F58A015AD

P304

Q36612301-65BD3B71-50F0-4B80-AD12-DEFAF3771983

P31

Q36612301-7DA0C823-CF99-4EE1-8DE9-B35CED0F7E87

P356

Q36612301-009C8264-09F7-4961-AE35-F938E26A6345

P407

Q36612301-D8A7097D-EF3B-4D25-B2AF-94D7744DDF57

P433

Q36612301-938FA506-1867-4559-9E22-B1469314C1C4

P478

Q36612301-197C62F8-3418-4A26-873C-A4C135F173B4

P577

Q36612301-048556CF-CEB5-4C84-A8FF-78437A889470

P5875

Q36612301-CB5F77A2-3261-4129-A9F2-17B0D7BA7851

P6179

Q36612301-7FD37513-64B6-48B7-BF95-B1B3AA8366EA

P698

Q36612301-4C14B560-A583-4D74-8425-783A06FBADE2

P921

Q36612301-46B0DF43-02BD-4154-97B2-AA56E3F8A05A

Q36612301-4A0D4943-E4D9-423B-BE53-C4FBEBF29D1A

Q36612301-B92E8651-44E8-4E79-A608-AE5CC0B86C71

P932

Q36612301-4CC06B0A-4F97-4CB9-8F49-7A795D2C2904

P356

P1433

British Journal of Cancer

P1476

Factors influencing p53 expres ...... utcome in multicentre studies.

@en

P2093

A G J van der Zee

http://www.w3.org/2001/XMLSchema#string

A P G Crijns

http://www.w3.org/2001/XMLSchema#string

G H de Bock

http://www.w3.org/2001/XMLSchema#string

H Hollema

http://www.w3.org/2001/XMLSchema#string

J Hall

http://www.w3.org/2001/XMLSchema#string

J M S Bartlett

http://www.w3.org/2001/XMLSchema#string

J Paul

http://www.w3.org/2001/XMLSchema#string

K A Oien

http://www.w3.org/2001/XMLSchema#string

K A ten Hoor

http://www.w3.org/2001/XMLSchema#string

P de Graeff

http://www.w3.org/2001/XMLSchema#string

P2860

ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways

p53, the cellular gatekeeper for growth and division

Surfing the p53 network

Cisplatin: mode of cytotoxic action and molecular basis of resistance

Tissue microarrays for high-throughput molecular profiling of tumor specimens

p53 protein stability in tumour cells is not determined by mutation but is dependent on Mdm2 binding.

Policy guidelines for the utilization of formalin-fixed, paraffin-embedded tissue sections: the UNC SPORE experience. University of North Carolina Specialized Program of Research Excellence.

Options for modulation of drug resistance in ovarian cancer.

Tissue microarray profiling of cancer specimens and cell lines: opportunities and limitations.

Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma.

P2888

P304

627-633

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/SJ.BJC.6603300

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

95

http://www.w3.org/2001/XMLSchema#string

P577

2006-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6905478

http://www.w3.org/2001/XMLSchema#string

P6179

1037670785

http://www.w3.org/2001/XMLSchema#string

P698

16880779

http://www.w3.org/2001/XMLSchema#string

P921

multicenter trial

P932

2360689

http://www.w3.org/2001/XMLSchema#string